The Veeva white paper highlights how COVID-19 accelerated the adoption of decentralized clinical trials (DCTs) and digital tools. Traditional trials face issues like slow enrollment, infrastructure burdens, and high dropout rates. DCTs use virtual data collection, reduce on-site visits, and digitize documentation, improving trial speed, patient access, and data quality. These methods broaden participant diversity, especially among younger and underserved groups. With cloud-based platforms, sponsors gain efficiency, compliance, and scalability. Veeva aims to make trials 25% faster and 25% less expensive through full digital transformation.

Join for free to read